Chronic Wound Treatment

Treatment of Chronic Wounds

APP is developing its technology into an Atmospheric Plasma Wound Applicator for chronic wound disinfection. Chronic wounds are an ideal environment for bacterial infection and biofilm formation. Recent data has shown that biofilm plays a significant role in the physiology of the majority of chronic wounds since the nature of growth of biofilm in the wound bed makes it resistant to systemic and topical antibiotics. Despite numerous advances, chronic wounds continue to be a treatment challenge and new technologies annihilating biofilms should be targeted when developing and testing wound therapeutics.

Bioburden in wounds includes devitalized tissue, colonizing microorganisms and bacteria in the form of biofilm. Chronic wounds are an ideal environment for bacterial infection and biofilm formation and delay healing. Current literature recognizes that over 60% of chronic wound specimens are characterized as containing biofilm.

Treatments of 20 min or less, using an APWA laboratory prototype, resulted in P. aeruginosa and MRSA biofilms that were 9 log CFU/membrane lower than those receiving no treatment while there was no viability loss even after 20 min of plasma treatment on keratinocytes. Keratinocytes, located in the epidermis, play important role in wound healing. They participate in epithelialization, wound closure and barrier restoration. Treatment of wound infection model showed plasma was very effective at killing P aeruginosa, S aureus strains including MRSA biofilm on the wounded skin of mice. Importantly, the application of atmospheric plasma did not cause any tissue damage to the skin or underlying tissue.

 

This research was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R44GM099207. 
The content is solely the responsibility of Advanced Plasma Products, Inc. and does not necessarily represent the official views of the National Institutes of Health.